首页> 外文期刊>Frontiers in Medicine >Age, Initial Central Retinal Thickness, and OCT Biomarkers Have an Influence on the Outcome of Diabetic Macular Edema Treated With Ranibizumab– Tri-center 12-Month Treat-and-Extend Study
【24h】

Age, Initial Central Retinal Thickness, and OCT Biomarkers Have an Influence on the Outcome of Diabetic Macular Edema Treated With Ranibizumab– Tri-center 12-Month Treat-and-Extend Study

机译:年龄,初始中央视网膜厚度和OCT生物标志物对患有Ranibizumab-Tri-Center 12个月的治疗和延伸研究治疗的糖尿病黄斑水肿的结果有影响

获取原文
获取外文期刊封面目录资料

摘要

Objective: We report the tri-center 1-year outcomes of a treat-and-extend (T&E) regimen in four-week intervals with ranibizumab for diabetic macular edema (DME). Methods: In this retrospective study, all eyes received 3 monthly loading injections of 0.5 mg ranibizumab, followed by a T&E regimen for DME. Regression models were used to evaluate the associating factors for visual and anatomical outcomes. Results: Ninety one eyes from 64 patients were enrolled. Mean LogMAR best-corrected visual acuity (BCVA) improved from 0.58 at baseline to 0.36 at month 12 and mean central retinal thickness (CRT) decreased from 411 μm at baseline to 290 μm at month 12. Younger age and eyes having thinner baseline CRT, with ellipsoid zone disruption (EZD), and without epiretinal membrane (ERM) were associated with better final CRT. Moreover, eyes with thicker baseline CRT tend to receive more injections. Among the parameters, only having ERM or EZD was associated with significant BCVA recovery. Conclusions: A T&E regimen with ranibizumab by 4-week intervals is effective in improving BCVA and reducing CRT with efficacy notable starting from the third month. Clinical parameters including age, initial CRT, and presence of ERM or EZD significantly influenced therapeutic outcomes. Moreover, the presence of ERM should not preclude DME patients from receiving anti-VEGF therapy. Future studies with larger cohorts are warranted.
机译:目的:我们以4周的间隔向糖尿病黄斑水肿(DME)以4周的间隔报告治疗和延伸(T&E)方案的三中心1年结果。方法:在这项回顾性研究中,所有眼睛都接受了每月加入0.5mg Ranibizumab的3个月,其次是DME的T&E方案。回归模型用于评估视觉和解剖结果的关联因子。结果:64名患者的九十一只眼睛注册。平均Logmar最佳校正的视力(BCVA)从基线0.58提高到0.36,在第12个,平均中央视网膜厚度(CRT)在1211μm以基线的411μm降低至290μm。年轻的年龄和眼睛具有较薄的基线CRT,含有椭球区域破坏(EZD),没有表闭膜(ERM)与更好的最终CRT相关。此外,具有较厚基线CRT的眼睛倾向于接受更多的注射。在参数中,仅具有ERM或EZD与显着的BCVA恢复相关。结论:通过4周间隔的Ranibizumab的T&E方案有效改善BCVA,并从第三个月开始使用疗效减少CRT。临床参数包括年龄,初始CRT和ERM或EZD的存在显着影响治疗结果。此外,ERM的存在不应排除DME患者接受抗VEGF治疗。有必要有较大的队列的未来研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号